Pharmacokinetics and metabolism of UK-383,367 in rats and dogs: A rationale for long-lived plasma radioactivity

Xenobiotica

Volumn 36, Issue 5, 2006, Pages 399-418

  Allan, G A ^a   Gedge, J I ^a   Nedderman, A N R ^a   Roffey, S J ^a   Small, H F ^a   Webster, R ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

Long lived plasma radioactivity; Oxadiazole cleavage; Oxamide; Unretained radioactivity

Indexed keywords

5 [4 CYCLOHEXYL 1 [2 (HYDROXYAMINO) 2 OXOETHYL]BUTYL] 1,2,4 OXADIAZOLE 3 CARBOXAMIDE; AMIDE; DRUG METABOLITE; METALLOPROTEINASE INHIBITOR; OXADIAZOLE DERIVATIVE; OXALIC ACID; OXAMIC ACID; OXAMIDE; PROCOLLAGEN C PROTEINASE; UK 383367; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOG; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG IDENTIFICATION; DRUG ISOLATION; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG STABILITY; DRUG STRUCTURE; FEMALE; HUMAN; ION EXCLUSION CHROMATOGRAPHY; MALE; NONHUMAN; RADIOACTIVITY; RAT; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SKIN SCAR;

ADMINISTRATION, ORAL; ANIMALS; BONE MORPHOGENETIC PROTEINS; CHROMATOGRAPHY, LIQUID; CICATRIX; DOGS; HUMANS; METALLOENDOPEPTIDASES; OXADIAZOLES; OXIDATION-REDUCTION; PLASMA; PROTEASE INHIBITORS; RADIOACTIVITY; RATS; RATS, SPRAGUE-DAWLEY;

CANIS FAMILIARIS;

EID: 33745101963     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.1080/00498250600618177     Document Type: Article

References (26)

1. Boll M, Foltz M, Rubio-Aliaga I, Kottra G, Daniel H. 2002. Functional characterisation of two novel mammalian electrogenic proton-dependent amino acid cotransporters. Journal of Biological Chemistry 277:22966-22973.
2. 0, a neutral amino acid transporter related to Hartnup Disorder. Journal of Biological Chemistry 279:24467-24476.
3. Choi MH, Jung BH, Chung BC. 1999. Identification of urinary metabolites of clemastine after oral administration to man. Journal of Pharmacy and Pharmacology 51:53-59.
4. 14C-acetohydroxamic acid. Journal of Pharmacology and Experimental Therapeutics 186(1):173-182.
5. Gardner IB, Walker DK, Lennard MS, Smith DA, Tucker GT. 1995. Comparison of the disposition of two novel combined thromobxane synthase inhibitors/thromboxane A2 receptor antagonists in the isolated perfused rat liver. Xenobiotica 25:185-197.
6. 0,+, exchange L-DOPA with neutral and basic amino acids in two clonal renal cell lines. Journal Membrane Biology 186:63-80.
7. Gyarmati L, Csontos A, Racz I, Satori EVA, Harsanyi K. 1976. Zum metabolismus des 3-[4-pyridyl]-5-[2-chlorphenyl]-1,2,4-oxdiazols in der ratte. Pharmazie 31:246-247.
8. Honohan T, Fitzpatrick FA, Booth DG, McGrath JP, Morton DR, Nishizawa EE. 1980. Hydrolysis of an orally active platelet inhibitory prostanoid amide in the plasma of several species. Prostaglandins 19:123-138.
9. Kalgutkar AS, Gardner I, Obach RS, Shaffer CL, Callegari E, Henne KR, Mutlib AE, Dalvie DK, Lee JS, Nakai Y, O'Donnell JP, Boer J, Harriman SP. 2005. A comprehensive listing of bioactivation pathways of organic functional groups. Current Drug Metabolism 6:161-225.
10. 14C] oxadiazole (SQ 18,506): 1. Reductive cleavage of the 1,2,4-oxadiazole ring. Xenobiotica 3:97-102.
11. Manchee GR, Eddershaw PJ, Ranshaw LE, Herriott D, Park GR, Bayliss MK, Tarbit MH. 1996. The aliphatic oxidation of salmeterol to α- hydroxysalmeterol in human liver microsomes is catalysed by CYP3A. Drug Metabolism and Disposition 24:555-559.
12. Manderville RA. 2005. A case for the genotoxicity of ochratoxin A by bioactivation and covalent DNA adduction. Chemical Research in Toxicology 18:1091-1097.
13. Nakai Y, Kanai Y, Tanayama S. 1977. Metabolic disposition of 3-[4-(1-ethoxycarbonyl-1-methyl-ethoxy)phenyl]-5-(3-pyridyl)-1,2,4,-oxadiazole (AT-308), a hypocholesterolemic agent in rats. Journal of the Takeda Research Laboratory 36:46-52.
14. Obach RS. 2004. Potent inhibition of human liver aldehyde oxidase by raloxifene. Drug Metabolism and Disposition 32:89-97.
15. Palacín M, Nunes V, Font-Llitjós M, Jiménez-Vidal M, Fort J, Gasol E, Pineda M, Feliubadaló L, Chillarón J, Zorzano A. 2005. The genetics of heteromeric amino acid transporters. Physiology 20:112-124.
16. Prockop DJ, Kivirikko KI. 1995. Collagens: Molecular biology, diseases, and potentials for therapy. Annual Review of Biochemistry 64:403-434.
17. Robinson LA, Wilson DM, Delaet NGJ, Bradley EK, Dankwardt SM, Campbell JA, Martin RL, Martin HE, Van HE, Walker KAM, Sullivan RW. 2003. Novel inhibitors of procollagen C-proteinase. Part 2: Glutamic acid hydroxamates. Bioorganic and Medicinal Chemistry Letters 13:2381-2384.
18. Sanderson L, Taylor GW, Aboagye EO, Alao JP, Latigo JR, Coombes RC, Vigushin DM. 2004. Plasma pharmacokinetics and metabolism of the histone deacetylase inhibitor trichostatin A after intraperitoneal administration to mice. Drug Metabolism and Disposition 32:1132-1138.
19. Sassard J, Pozet N, McAinsh J, Legheand J, Zech P. 1977. Pharmacokinetics of atenolol in patients with renal impairment. European Journal of Clinical Pharmacology 12:175-180.
20. Strolin Benedetti M, Coupez R, Whomsley R, Nicolas JM, Collart P, Baltes E. 2004. Comparative pharmacokinetics and metabolism of levetiracetam, a new anti-epileptic agent, in mouse, rat, rabbit and dog. Xenobiotica 34:281-300.
21. Sundberg C, Ivarsson M, Gerdin B, Rubin K. 1996. Pericytes as collagen-producing cells in excessive dermal scarring. Laboratory Investigation 74:452-466.
22. Tang-Liu DD, Tozer TN, Riegelman S. 1982. Urine flow-dependence of theophylline renal clearance in man. Journal of Pharmacokinetics and Biopharmaceutics 10:351-364.
23. Verrey F, Ristic Z, Romeo E, Ramadan T, Makrides V, Dave MH, Wagner CA, Camargo SMR. 2005. Novel renal amino acid transporters. Annual Review of Physiology 67:557-572.
24. Yabuki M, Shono F, Nakatsuka I, Yoshitake A. 1993. Novel cleavage of the 1,2,4-oxadiazole ring in rat metabolism of SM-6586, a dihydropyridine calcium antagonist. Drug Metabolism and Disposition 21:1167-1169.
25. Yang L, Liu L, Olsen BA, Nussbaum MA. 2000. The determination of oxalic acid, oxamic acid and oxamide in a drug substance by ion-exclusion chromatography. Journal of Pharmaceutical and Biomedical Analysis 22:487-493.
26. Zhang D, Krishna R, Wang L, Zeng J, Mitroka J, Dai R, Narasimhan N, Reeves RA, Srinivas NR, Klunk LJ. 2005. Metabolism, pharmacokinetics, and protein covalent binding of radiolabelled Maxipost (BMS-204352) in humans. Drug Metabolism and Disposition 33:83-93.